Role of Neurohumoral Modulation in Congestive Heart Failure: Focus on the New Generation Calcium Channel Blockers

Michel White

ABSTRACT
Despite improvement in the control of risk factors such as coronary artery disease and systemic hypertension, the incidence of congestive heart failure (CHF) is actually increasing. Wide use of angiotensin-converting enzyme inhibitors has influenced the survival of patients in the community but mortality in patients with advanced disease remains about 15% after one year.

It has become clear that, while neurohumoral activation is important in supporting cardiac function after the loss of myocardial tissue following infarction, such simulation contributes to the further deterioration of the cardiac muscle and this is detrimental in patients with CHF. An increase in regional cardiac adrenergic activity has been associated with an adverse outcome in patients with CHF. The effects of certain drugs that work to dilate the arteries without activating the overall neurohumoral system, and more specifically the adrenergic nervous system, may help to explain the success of these medications in CHF. Current trials indicate second-generation calcium channel blockers such as amlodipine are well tolerated and improve the neurohumoral milieu in CHF. Accordingly, these agents may prove useful as adjunctive treatments for congestive heart failure.

Key words: calcium channel blockers, cardiac adrenergic activity, congestive heart failure, neurohumoral system

RÉSUMÉ
Rôle de la modulation neurohormonale dans le traitement de l’insuffisance cardiaque congestive : plein feux sur la nouvelle génération d’inhibiteurs des canaux calciques.

Malgré les avancés dans la maîtrise des facteurs de risque comme les coronaropathies et l’hypertension, l’incidence de l’insuffisance cardiaque congestive (ICC) est actuellement à la hausse. L’usage répandu des inhibiteurs de l’enzyme de conversion de l’angiotensine a eu une influence sur la survie des patients dans la communauté, mais la mortalité chez les patients dont la maladie est avancée est toujours d’environ 15 % après un an.

Il est maintenant évident que, bien que l’activation neurohormonale joue un rôle important dans le maintien de la fonction cardiaque suite à une nécrose du tissu myocardique consécutive à un infarctus, la stimulation cardiaque soutenue contribue à la détérioration du muscle cardiaque et qu’elle est délétère chez les patients atteints d’ICC. Un accroissement de l’activité adrénergique cardiaque locale a été associée à une issue indésirable chez les patients atteints d’ICC. Les effets de certains médicaments qui ont une activité dilatatrice sur les artères, mais non sur tout le système neurohumoral et plus particulièrement le système sympathique, pourraient expliquer le succès de ces médicaments dans le traitement de l’ICC. Les essais actuels révèlent que les inhibiteurs des canaux calciques de deuxième génération, comme l’amlodipine, sont bien tolérés et améliorent le milieu neurohumoral des patients souffrant d’ICC. Par conséquent, ces agents pourraient s’avérer utiles comme traitement adjuvant dans l’insuffisance cardiaque congestive.

Mots clés : activité adrénergique cardiaque, inhibiteurs des canaux calciques, insuffisance cardiaque congestive, système neurohumoral

Can J Hosp Pharm 1997;50:121-126

INTRODUCTION
Congestive heart failure (CHF) affects about 1% of the North American population.1 The two leading causes of CHF are coronary artery disease and systemic hypertension.2 Despite improvement in the control of these risk factors, and despite a decrease in the incidence of coronary disease over the last 15 years, the incidence of heart failure is actually increasing.3 This is due in part to the aging population. Furthermore, the costs related to this morbid condition are greater than those for the treatment of all cancers combined.4

The treatment of CHF has evolved significantly over the last decade. The most important change to the standard

Michel White, MD, FRCP(C), is an Assistant Professor of Medicine, Université de Montréal, Montréal, Québec, and a Cardiologist at the Institut de Cardiologie de Montréal.

Address correspondence to: Michel White, MD, FRCP(C), Institut de Cardiologie de Montréal, 5000 rue Belanger, Montréal, Québec. H1T 1C8.

Acknowledgments: This article is based on an oral presentation at the “Calcium Antagonists and their Role in the Canadian Healthcare Community” symposium funded by Pfizer Canada held in conjunction with the Canadian Society of Hospital Pharmacists meeting on February 4, 1996 in Toronto, Ontario.
regimen, which has affected both the functional capacity and survival of patients suffering from this condition, has been the use of angiotensin-converting enzyme (ACE) inhibitors. The use of this class of agent has increased survival by about 25 to 30%. Their broad use has also influenced the survival of patients in the community. Nevertheless, mortality in patients with advanced disease remains about 15% after one year and close to 50% after five years. Statistics from the SOLVD trial indicate that nearly half of patients with symptoms of CHF and with a left ventricular (LV) ejection fraction, less than 35% treated with enalapril died or were hospitalized for decompensated CHF over the duration of the study. In addition, the SOLVD trial also demonstrates the use of enalapril was contraindicated in 11% of patients potentially eligible to receive it. Finally, some clinical data suggest the effect of ACE inhibition may be lost over time, and some neurohormones such as aldosterone, although initially suppressed by ACE inhibitor, may "escape" and increase over time. Thus, these observations have justified the search for the use of alternative and/or adjunctive treatments in CHF.

The purpose of this review is to present the importance of the neurohumoral activation in CHF based on the results of some important contemporary clinical trials. The rationale for the use of adjunctive agents such as the new generation calcium channel blockers in patients with CHF is also presented.

**Neurohumoral Activation and Adverse Outcome**

Myocardial injury caused by myocardial infarction (MI) or other viral, toxic, or metabolic diseases results in an early increase in vasoconstrictor hormones such as norepinephrine, renin, angiotensin, and endothelin. The release of these hormones occurs early in the course of the disease before symptoms such as dyspnea and fatigue appear. The elevation in circulating levels of these substances causes an increase in the pumping ability of the damaged myocardium and helps to sustain blood pressure by enhancing cardiac output and causing peripheral vasoconstriction. These mechanisms are important to support cardiac function after the loss of myocardial tissue. However, chronic stimulation causes myocardial damage and likely contributes to further deterioration of the cardiac muscle. In fact, increased circulating levels of norepinephrine, renin, or endothelin, as well as other surrogates of chronic neurohumoral activation such as hyponatremia, have all been significantly related to a poor outcome in patients with CHF (Figure 1). In response to this chronic elevation of vasoconstrictor hormones, there is a parallel increase in vasodilatory hormones such as prostaglandin and atrial natriuretic peptides. As with the vasoconstrictive substances, the elevation of these counteracting vasodilatory hormones has been associated with an adverse outcome in CHF patients. Interestingly, while chronic systemic activation is related to survival in CHF, an increase in regional cardiac adrenergic activity appears to be even more powerfully related to a poor outcome. In a recent study by Kaye and coworkers, the cardiac regional release of norepinephrine or norepinephrine "spillover" was a significantly better predictor of adverse outcome than systemic plasma norepinephrine levels (Figure 2). This finding suggests that any intervention that lowers
cardiac regional adrenergic drive will likely confer a significant decrease in mortality.

The beneficial effects of certain drugs on the neurohumoral milieu help to explain the success of CHF medications that work to dilate the arteries without activating the overall neurohumoral system, and more specifically the adrenergic and the renin-angiotensin-aldosterone systems (Table I).1,3 The use of ACE inhibitors improves the neurohumoral status.3,10 For example, enalapril improves survival and prevents the development of symptoms of CHF and clinical deterioration in patients with chronic CHF of any etiology.3,4 Similarly, captopril, lisinopril, and ramipril decrease mortality when administered early after a myocardial infarction, and in the case of captopril and lisinopril, even when there is no clinical evidence of CHF.17,24,34 The benefit of a vasodilator that also improves the neurohumoral status, in comparison with direct-acting agents such as hydralazine, becomes more apparent in the presence of high neurohumoral activation. In the VHeFT-II trial, in which the combination of hydralazine and nitrates was compared with enalapril, the excess mortality in the group of patients treated with hydralazine/nitrates was restricted to those with high circulating levels of norepinephrine.29 In addition, the reduction in mortality related to ACE inhibition was also significantly greater in very sick patients compared to those with milder heart failure symptoms.3,4

Some other agents improve symptoms and/or survival such as β-blocker or digoxin without activating the neurohumoral system. β-adrenergic blockade of second and third generation calcium channel blockers such as metoprolol11 or carvedilol22 improves symptoms and ejection fraction and reduces hospitalization for heart failure. Captopril has also been shown to improve survival25 in CHF due to ischemic or dilated cardiomyopathy. Although these agents cause little change in the systemic level of norepinephrine, they significantly decrease the transmyocardial norepinephrine balance and, thus, regional cardiac adrenergic activity.23 Digoxin is an inotrope which enhances the parasympathetic tone and baroreflex responsiveness.24 This agent improves functional capacity, and in the recently presented DIG trial,13 despite a neutral effect on survival, reduces the risk for the deterioration and hospitalization for CHF. Finally, angiotensin-II blockers such as losartan can be used in patients intolerant to ACE inhibitors as they provide similar benefits for up to 12 weeks.26 Whether an angiotensin-II blocker causes similar benefits to an ACE inhibitor in the longer term is currently being investigated.

While vasodilator and neurohumoral modulators improve survival, pharmacologic agents that activate the neurohumoral system increase mortality despite a beneficial effect on functional class and exercise tolerance. For example, chronic administration of xamoterol, a β,-agonist,27 and milrinone, a phosphodiesterase inhibitor,28 increases mortality and activates the vasoconstrictive neurohumoral system when administered orally in patients with severe CHF (Table I). In the PROFILE study, the effect of a direct vasodilator, flosequinar, was compared to placebo in patients with moderate to severe heart failure.29 Flosequinar induces a mild increase in heart rate and, thus, activates the adrenergic nervous system. Despite a functional class improvement noted early in the trial, an increased mortality was observed at one year in patients treated with flosequinar causing premature cessation of the trial. As a whole, these data indicate that even in the presence of improved pump function, activation of the neurohumoral system is associated with poor survival.

### Role for Calcium Channel Blockers

Early studies involving the use of calcium channel blockers in CHF were not promising. In fact, although short-acting nifedipine improved systemic hemodynamics when given acutely, chronic administration of this agent to patients with CHF was associated with worsening heart failure.30 Similar observations were reported with diltiazem.31 In that study, the chance of developing CHF in patients treated with diltiazem after an MI was directly related to the magnitude of impairment in systolic function at the time of randomization. The mechanism for this worsening in cardiac function in patients chronically treated with these agents is likely related to chronic neurohumoral activation.32 In fact, potent vasodilation by these

Table I. Natural History and Treatment of Heart Failure as Defined by Some of the Large, Contemporary, Placebo-Controlled Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Study Drug</th>
<th>Patient Population</th>
<th>Mean FU (months)</th>
<th>RR</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>VHeFT-1</td>
<td>H2/NI</td>
<td>Class II-III</td>
<td>27</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>CONSENSUS-1</td>
<td>Enalapril</td>
<td>Class IV</td>
<td>6</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>SOLVD, tTT</td>
<td>Enalapril</td>
<td>CHF, EF ≤ 35%</td>
<td>41</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>SOLVD, pvt</td>
<td>Enalapril</td>
<td>Asymptomatic, EF ≤ 35%</td>
<td>37</td>
<td>0.82</td>
<td></td>
</tr>
<tr>
<td>SAVE</td>
<td>Captopril</td>
<td>Post-MI, EF ≤ 40%</td>
<td>42</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td>Xamoterol</td>
<td>Xamoterol</td>
<td>Class III-IV</td>
<td>3</td>
<td>2.54</td>
<td></td>
</tr>
<tr>
<td>PROMISE</td>
<td>Milrinone</td>
<td>Class III-IV</td>
<td>6.1</td>
<td>1.27</td>
<td></td>
</tr>
</tbody>
</table>

RR = relative risk, NA = neurohumoral activation

Adapted from Armstrong PW et al. Circulation 1994;88:2941-52 (ref. 15)

trt = treatment, pvt = prevention, H2 = hydralazine, NI = nitrate
short-acting calcium channel blockers stimulates the baroreflex responses, increasing sympathetic discharge to compensate for the negative inotropic effect of these agents on the diseased myocardium. However, chronic neurohumoral activation, which appears to cause myocyte hypertrophy, calcium-mediated cellular damage and increased oxidative stress, eventually contributes to further deterioration of the cardiac muscle.

**Newer Calcium Channel Blockers**

The new generation of calcium channel blockers has recently shown promising results in patients with CHF. Early work performed by Packer and colleagues showed that administration of amlodipine for eight weeks improves exercise time and decreases circulating levels of norepinephrine in 118 patients with class II to III symptoms treated with diuretics and digitalis and most of them (67%) with an ACE inhibitor (Table II). This study was important because it demonstrated that further vasodilation with calcium channel blockers was safe and could lower norepinephrine levels. This finding prompted the Prospective Randomized Amlodipine Survival Evaluation in Heart Failure (PRAISE) study. In this trial, NYHA Class III and IV patients with ejection fractions less than 30% and receiving triple background therapy of ACE inhibitors, digoxin and diuretics were randomized to receive amlodipine or placebo. The patients treated chronically with amlodipine exhibited a trend toward survival (p = 0.07) after a median follow-up of 13.8 months. Interestingly, no significant changes in survival were observed in the group with heart failure caused by ischemic heart disease. In contrast, the patients in whom heart failure was caused by dilated cardiomyopathy exhibited a 45% reduction in mortality when treated with amlodipine (p = 0.001). In that study, amlodipine was as well tolerated as placebo, with a discontinuation rate of 16% for placebo versus 14% for the group receiving amlodipine. Peripheral and pulmonary edema occurred more often while uncontrolled hypertension and angina occurred less often in the amlodipine group. Nevertheless, despite the increase in pulmonary edema, the amlodipine treated group yielded a decrease in life-threatening arrhythmias and death, two events generally associated with the clinical progression of CHF.

The mechanisms underlying such important differences in the response of ischemic versus idiopathic dilated cardiomyopathy to amlodipine remain largely unknown. Nevertheless, significant differences exist between these two conditions. The myocardium injured by coronary artery disease has a mix of scarred areas chronically deprived of blood supply, and areas of viable but poorly functioning cardiac muscle. In addition, the quantity of remaining noninfarcted myocardium is less in ischemic cardiomyopathy and yields more significant abnormalities with regard to the beta adrenergic neuroeffector pathways, such as less β1-receptor downregulation and more uncoupling from myocardial contraction. Consequently, ischemic cardiomyopathy might be less amenable to pharmacologic modulation than heart failure caused by idiopathic dilated cardiomyopathy. These hypotheses remain speculative and more work needs to be done to improve our understanding of the differences between these two conditions. The PRAISE-II trial is now underway and will involve only patients with dilated cardiomyopathy. Patients with severe CHF treated with triple therapy will be randomized to receive amlodipine versus placebo. Many substudies will be performed and combined with the main trial in order to better understand the effect of amlodipine on the failing myocardium.

The VHFT III trial was a study of felodipine in patients with mild to moderate CHF. In this study, patients with class II to III symptoms and ejection fraction below 45% and/or a cardiothoracic ratio greater than 55% were randomized to receive felodipine versus placebo in addition to triple drug therapy. Two-hundred and forty four (224) patients were randomized to receive felodipine and 227 patients received placebo, and were followed for three years. Similar to amlodipine, felodipine was well tolerated and had a neutral effect on survival. However, the mortality rate was very low in both the felodipine and the placebo-treated patients (about 20% at three years), and thus the study lacked the power to detect a significant effect of felodipine on survival. Despite these limitations, it is possible to conclude that felodipine is safe to use in patients with mild to moderately severe CHF.

The results from these trials have important consequences for clinical practice. It is safe to use amlodipine as an anti-ischemic agent in patients who have angina and CHF. Also, some patients with heart failure, especially when heart failure is due to or associated with systemic hypertension, may continue to exhibit systemic hypertension or may present significant mitral valvular

| Table II. Improvement in Exercise Time and Symptoms, and Decrease with Amlodipine |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                 | Placebo | Amlodipine |
| Change in exercise time (sec)   | +12 ± 13 | +22 ± 13 | +30 ± 13 | +62 ± 30 ± |
| % of patients with improvement in symptoms | — | +29 | — | +55% |
| Change in norepinephrine levels (pg/mL) | — | +30 | — | —95% |

*p < 0.05 (8 weeks vs. baseline)
†p < 0.05 (amlodipine vs. placebo)
Adapted from Packer M. J Am Coll Cardiol 1991; 17:274A (ref. 34)
regurgitation despite high doses of ACE inhibitor. Amlodipine and felodipine may help to provide further vasodilation without activating the neurohumoral system.

In conclusion, unlike short-acting first-generation agents, the new generation of dihydropyridine calcium channel blockers which have better vascular selectivity and improved pharmacokinetics appear to be safe when used in moderate and even severe CHF. These promising results provide the clinician with additional tools to improve symptoms and cardiac function in patients with CHF and concomitant conditions such as angina or hypertension. Currently under investigation is a group of new agents, such as mibefradil, which block L- and T-calcium channels and a large survival trial involving patients with heart failure is currently underway (the MACH-I study). The results from this trial and from the PRAISE-II study should provide additional valuable insight into the role of such agents in the treatment of CHF.

REFERENCES

30. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of


37. Cohn JN. The V-HeFT-III (Vasodilator-Heart Failure-III) trial: background and main results. Presented at the American Heart Association Annual meeting, November 1985, Anaheim, CA.